Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective study evaluating the feasibility of treatment planning integrating lung perfusion PET/CT using Ga68-MAA to preserve functional lung areas during stereotactic body radiation therapy (SBRT).
Lung perfusion PET / CT is a new imaging modality based on the use of the same cold molecules as those used for a conventional perfusion lung scan. Similartly, perfusion images are obtained after intravenous administration of human albumin macroaggregates, which are embolized in pulmonary capillaries according to pulmonary blood flow. However, these cold molecules are radiolabeled, not with Technetium99m, but with Gallium68, a ß + isotope, allowing image acquisition with PET technology. The same physiological processes are therefore observed with conventional scintigraphy PET imaging, but PET is an intrinsically superior technique for image acquisition, with greater sensitivity, better spatial and temporal resolutions and the possibility to perform respiratory-gated acquisition, allowing a better definition of the pulmonary functional volumes.
The aim is to evaluate the feasability of functional lung avoidance planification using lung perfusion PET/CT imaging during SBRT.
Patients will benefit from a pre-treatment functional assessment including PET/CT imaging.
The treatment planning will be carried out in 2 stages:
A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification | Experimental | All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:
The treatment planning will be carried out in 2 stages:
A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pre-therapeutic imaging test | Drug | The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously. |
| Measure | Description | Time Frame |
|---|---|---|
| Patients with a dose reduction to the functional lung (estimated during functional planning). | Percentage of patients for whom it is possible to reduce the dose to the functional lung (estimated during the functional planning). A reduction in the dose to the functional lung will be defined by:
| Baseline, one week after lung perfusion PET / CT scan using Ga68-MAA |
| Measure | Description | Time Frame |
|---|---|---|
| Impact of lung perfusion PET / CT scan on lung activity during SBRT (stereotactic body radiation therapy) planning | Percentage of activity included in the V20Gy with the anatomical planning and the functional planning. | Baseline, one week after lung perfusion PET / CT scan using Ga68-MAA |
| Impact of lung perfusion PET / CT scan on lung activity during SBRT (stereotactic body radiation therapy) planning |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU de Brest | Brest | Brest Cedex | 29609 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40591115 | Derived | Le Roux PY, Le Pennec R, Bourbonne V, Blanc-Beguin F, Pavoine M, Kerleguer K, Mauguen M, Pradier O, Salaun PY, Lucia F, Bourhis D. Pulmonary uptake value (PUV): a new quantification method for lung PET/CT imaging. EJNMMI Res. 2025 Jul 1;15(1):79. doi: 10.1186/s13550-025-01274-y. |
Not provided
Not provided
All collected data that underlie results in a publication
Data will be available after the publication of result and ending fifteen years following the last visit of the last patient
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Percentage of functional lung volume included in the V20Gy with anatomical planning and during functional planning |
| Baseline, one week after lung perfusion PET / CT scan using Ga68-MAA |
| Pulmonary toxicity at 3 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-C30 : European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Cancer module 30) at 3 months | At 3 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 3 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-LC13 :European Organisation for Research and Treatment of Cancer- Quality of Life Questionnaire - Lung Cancer module 13) at 3 months | At 3 months after SBRT( stereotactic body radiation therapy) |
| Pulmonary toxicity at 6 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-C30 : European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire -Cancer module 30) at 6 months | At 6 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 6 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-LC13 : European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Lung Cancer module 13) at 6 months | At 6 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 9 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-C30 : European Organisation for Research and Treatment of Cancer -Quality of Life Questionnaire - Cancer module 30) at 9 months | At 9 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 9 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-LC13 : European Organisation for Research and Treatment of Cancer -Quality of Life Questionnaire - Lung Cancer module 13) at 9 months | At 9 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 12 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-C30 : European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Cancer module 30) at 12 months | At 12 months after SBRT (stereotactic body radiation therapy) |
| Pulmonary toxicity at 12 months | Pulmonary toxicity defined according to EORTC (European Organisation for Research and Treatment of Cancer) criteria (Common Terminology Criteria for Adverse Events 5.0, EORTC QLQ-LC13 : European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Lung Cancer module 13) at 12 months | At 12 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at Day 0 (inclusion) | Results of EuroQol (EQ-5D-5L) questionnaire | Baseline, Day 0 |
| Dyspnea at Day 0 (inclusion) | Results of Pulmonary Function testing (PFT) : FEV1 | Baseline, Day 0 |
| Dyspnea at Day 0 (inclusion) | Results of Pulmonary Function testing (PFT) : FEV1/FVC | Baseline, Day 0 |
| Dyspnea at Day 0 (inclusion) | Results of 6 minutes Walk Test (6MWT) | Baseline, Day 0 |
| Dyspnea at 3 months | Results of EuroQol (EQ-5D-5L) questionnaire | At 3 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 3 months | Results of Pulmonary Function testing (PFT) : FEV1 | At 3 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 3 months | Results of Pulmonary Function testing (PFT) : FEV1/FVC | At 3 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 3 months | Results of 6 minutes Walk Test (6MWT) | At 3 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 6 months | Results of EuroQol (EQ-5D-5L) questionnaire | At 6 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 6 months | Results of Pulmonary Function testing (PFT) : FEV1 | At 6 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 6 months | Results of Pulmonary Function testing (PFT) : FEV1/FVC | At 6 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 6 months | Results of 6 minutes Walk Test (6MWT) | At 6 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 9 months | Results of EuroQol (EQ-5D-5L) questionnaire | At 9 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 9 months | Results of Pulmonary Function testing (PFT) : FEV1 | At 9 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 9 months | Results of Pulmonary Function testing (PFT) : FEV1/FVC | At 9 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 9 months | Results of 6 minutes Walk Test (6MWT) | At 9 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 12 months | Results of EuroQol (EQ-5D-5L) questionnaire | At 12 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 12 months | Results of Pulmonary Function testing (PFT) : FEV1 | At 12 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 12 months | Results of Pulmonary Function testing (PFT) : FEV1/FVC | At 12 months after SBRT (stereotactic body radiation therapy) |
| Dyspnea at 12 months | Results of 6 minutes Walk Test (6MWT) | At 12 months after SBRT (stereotactic body radiation therapy) |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |